We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I believe the double line gap is an LSE glitch, seems to happen to me, if I start a new line in a post, it shows as a double line gap. His post looks like a cut & paste from information he has found, it's actually quite significant information! Basically, Eroxon can be used on the femail erogenous zone for more pleasure, however, it will need to go though trials and probably need a new name, maybe also a change of colour to pink, and add some flavouring
I don’t know about you, but I found it very laborious trying to read it’s posts, so much so, I gave up after about the 5th double line entry. What’s with the two line approach ?…… I wonder what’s wrong with just a summary, I’m sure many more would be interested in just a summary.
Yes, the blue pill manufacturers would want this product, ether to complement their product, or to stop it being a competitor! They could then call it: Viagra Gel.
Yes ,i think potentially it could be a takeover target. i posted a few days ago,that this might be a welcome outcome for the board for various reasons.however,i think it is going to need a much longer data period re sales etc,before this becomes a realistic possibility.18 months to 2 years at a minimum i would have thought.just my opinion of course.
So many new markets appointed and yet the SP remains hovering around 50p_
Surely FUM is a great target for a takeover?
What is your source of information?
“the universal sex aid for women”
futura have stated their intention of extending the eroxon pipeline and this post is an attempt at
understanding what this 2 nd version of med3000 is all about. this leads to a number of bold
predictions about how events will unfold which every investor should research to form an opinion
about the predictions.
a previous post(med3000 for women #4/ orgasm by deduction) concluded that female orgasmic
disorder(fog) involving women experiencing orgasmic dysfunction would become futura’s main
focus for development. however, this does not mean that fog can be treated with med3000. futura
will use fog as a frame of reference for their clinical studies but quietly move away from the negative
connotation of fog itself.
futura’s intention for med3000 is that it could become a “pro-orgasmic sex-aid” that will be of
interest to most of the sexually active female population in the developed world; the potential
customers for med3000 number in the hundreds of millions. these women are capable of orgasm “by
other means”, but when it comes to sexual intercourse itself, they fail to have an orgasm. this is the
secret, silent, unspoken problem facing most heterosexual couples in the developed world and beyond.
many men live “in denial” of this situation and this is a source of tension in a relationship. futura want
to make things easier for couples who live with the tendency of “orgasmic surplus” for men and an
“orgasmic deficit” for women during sexual intercourse. they want to enable heterosexual couples to
become “lost” in the act of intercourse itself without having to “overthink” what they are doing. futura
intend to make a simple claim for med3000: “helps you achieve orgasm during intercourse”. they
also want to make a second claim for med3000: “helps you achieve a more intense orgasm”. this
second claim will make med3000 appealing to women who currently have no problem achieving
orgasm during intercourse. it will also make it attractive to ******* women who achieve orgasm “by
other means”; so med3000 really is “the universal sex aid for women”.
futura will approach the highly complex subject of the female orgasm from a “mainstream
perspective”; that is to say that they will take the view that the majority of orgasms during intercourse
are triggered by direct or indirect clitoral stimulation (masters and johnson, 1966; hite, 1976). “direct
stimulation” means it is “intentional”; “indirect stimulation” is not intentional, it just “happens” as the
clitoris is indirectly stimulated during the coital act. some researchers estimate that approximately
25% of women always have orgasm from intercourse, while 50% of women achieve orgasm from
intercourse about half the time. about 25% rarely or never achieve orgasm from intercourse, (lloyd,
2005) these estimates understate the situation as many of these orgasms involve direct stimula
Futura will only recruit healthy women into their clinical studies who are capable of orgasm “by other
means” but self report difficulties in achieving orgasm from intercourse alone. They will separate these
women into different groups according to their stated difficulty of achieving orgasm during intercourse.
The clinical endpoint is to demonstrate that MED3000 when applied to the clitoris enhances a woman’s
ability to achieve orgasm during intercourse without direct stimulation. Futura will tell the women “you
must not intentionally stimulate the clitoris during intercourse!” They will also use “orgasm rating
scales” to attempt to evaluate the quality of the orgasm. Futura know that MED3000 when applied to
the clitoris will stimulate the nerves that lie within the tissue. They know that these nerves contain
“vesicles” containing “excitatory neurotransmitters”; these are chemicals which enable nerves to com-
municate with each other. Futura agree with “mainstream” researchers that orgasm from intercourse
alone is by “indirect stimulation” during intercourse(Masters and Johnson, 1966; Hite, 1976). So Fu-
tura’s premise is that MED3000 when applied to the clitoris will “supercharge” the nerves in the clitoris
to the extent where indirect stimulation during intercourse will be sufficient to induce orgasm in most
women.
The observation that Futura are poised to reveal a “pro-orgasmic sex- aid” which will be of interest to
the hundreds of millions of sexually active women in the developed world has profound implications
for investors. This is not a “shame product” destined for an unfortunate minority of the population. Fe-
male celebrities will be proud to be associated with “the universal sex aid for women”; this product
could rapidly become famous throughout the world as most women will be curious to experience its
claims.
The stock market is “forward thinking,”it could see obscure contracts, FDA approval, marketing part-
ners etc; it was not moved. Meanwhile, looking at Futura’s share price, there is no evidence that the
stock market has seen Futura’s latest project. The first dramatic movement in Futura’s share price will
happen when the stock market beholds “The Monster” for the first time, shortly after Futura announce
the clinical studies for MED3000 and the stock market finally perceives the scale of Futura’s ambition.
It will perceive the high probability of success with MED3000 just like it predicted FDA approval etc.
It will see potential sales of GBP 10 billion; then GBP 15 billion and more: no one will really know as
there has never been a consumer health product quite like it. The Futura share price will begin to reflect
the potential magnitude of the world’ s first universal sex aid for women.
Hite, S., 1976. The Hite Report. Macmillan, New York
Lloyd, E., 2005. The Case of the Female Orgasm: Bias in the Science of Evolution. Harvard
Unive
My apologies Bottom Feeder for puncturing your raw nerve...........................................
Your figures were inaccurate - FACT.
Please provide me with private contact details and I will gladly devote time to running through your previous email to correct your anomalies.
Like you I am long and strong of this share.
Seeing lots of small simultaneous price and times trades going through, think this is institutions using a bot (programmed computer) buying/selling
DarthInvestor: I'm already heavy on Fum in my portfolio. I'm almost £50k invested thus far, so hopefully that gives a clue how good I think the future is.
The share market is extremely difficult to call at present and for the next 6 months and I've decided that FUM provides one of the few 'guaranteed' double digit+ returns in the next 6 months.
So FUM is one of those shares I've invested heavily in on the basis that I'm happy to sit back and wait for a very good return.
I seldom ever listen to trolls who try to ramp shares and claim multibagger capabilities.
But.... FUM (imho) is now one of the few I actually think will double my investment within a year.
So, I'm happy to wait up to 12 months to make £50k+ profit.
And shall be topping up regularly.
Really hoping this will prove my loyalty as an actual long term investor.
P.S. as always "STRONG, STRONG BUY"
Gla
Yes, strong volume is a bullish indication, shows interest.
What we are really waiting for is USA distribution and sales. Then its woooooosh.
Volume up to 500k by 9am. Seems like something may be happening. Volume has really died down recently.
Interesting point Martinelwick but surely no RNS required ?
FUTURA is involved in the manufacturing of the gel NOT SALES OR DISTRIBUTION.
That is down to COOPER in Europe and the U.K.
COOPER is a privately owned company and as such is not subject to Stock Exchange disclosure rules .
Cooper certainly seem to be doing a brilliant job at the moment.
Roll on next Monday but it’s a shame that EROXON sales will only indicate two months of the six month interim period.
Good luck all long term FUMSTERS !
Arturo.
Clearly Boots had a time limited exclusive deal with FUM.That has expired and Eroxon is now available in many other outlets.This is very good news.My question is why was no RNS issued informing the market about this fundamental change.
One argument might be that clearly it hasn’t proved to be price sensitive given the ongoing stagnation of the share price.
My suspicion is that FUM want to trumpet this development next week.
However it should not be the case that but through the postings on this BB we would be completely ignorant of an important commercial development.
Too true bottom, this mid term report will only cover the weak launch for 2 months so will give indication as to royalties and maybe actual sales figures, units sold etc. This will be something to try and quantify their success, after that period more countries launched, mass tv adverts in UK and the saudi's will be selling for 3 months uo to year end, and the 4 mil upfront us payment so indeed their full year report will be banging. Id get in now if i wasnt already in, next year may not be around 50 zone prior to that yr end financials. :)
I think a lot of us are going to be very happy this time next week.
GLA.
Henners: By all means make stupid remarks on other peoples comments such as mine.
there is absolutely nothing wrong with my figures. They correlate with all the previous RNS figures.
If you think they are wrong then why don't you ACTUALLY wirte down the corrected figured rather than simply trying to 'imply' I, or anyone else is wrong.
You seem to think I am somehow 'rubbishingn' FUM. Yet my comment is FAR FROM IT. It is actually saying that the Full Year REport is going to be the Real Story of just how well the company has done.
I even propose that they will become net positive.
So get you own facts straight and stop trying to Troll others.
By all means if you don't like what I say...... then filter me.
P.S. You 'mightt' even notivve that I mark my opinion as £Strong Buy" on all my posts ...... IDIOT!
It's also for sale online at ChemistDirect for £19.99 with free postage over £35. No reviews on that site yet.
Seeing this pop up on shelves that get MASSIVE foot fall, I must admit I can see some explosive numbers coming. Not a pump but I used to work in FMCG and as soon as products like this hit big retail shelves the numbers shoot up. The SP has a very positive future imho. Just as an additional piece, getting listed in Tesco is NOT easy, that I can tell you from first hand experience. Anyway just some thoughts, great board, great product, sales momentum will be boiling
Thanks for checking this … let’s hope they keep on eye on displays etc
It was shown earlier today on Tesco website out of stock and £24.99.
But that disappeared. Probably launch tomorrow?
But can be ordered online at Superdrug now at £24.99.
Strap into your seats.
Yep, just been to our local Tesco. It's on the shelf in the pharmacy, but tucked away in a corner. A single line of boxes, no price on the shelf edge and no point of sale material, unlike the little blue pill which has lots of point of sale material on the front counter and several lines of boxes in a prominent position behind the counter. Wonder if that's because of a difference in margin/profit.
Also in select Superdrug stores and available to order online at Superdrug. (just checked)